Compare ClearPoint Neuro Inc (CLPT) vs Freshworks Inc (FRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Freshworks Inc — how do they compare? ClearPoint Neuro Inc trades at $15.2 (market cap $454.21M), while Freshworks Inc trades at $11.97 (market cap $3.31B). The key difference: Freshworks Inc is far larger — about 7.3× ClearPoint Neuro Inc's market cap, and Freshworks Inc is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| CLPT | FRSH | |
|---|---|---|
Market Cap | $454.21M | $3.31B |
Sector | Health | Technology |
52-Week High | $29.60 | $13.97 |
52-Week Low | $8.66 | $6.88 |
Enterprise Value | $488.79M | $2.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $15.18, up 4.19% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue growth but missed earnings expectations with a $0.38 loss per share. Despite negative profitability metrics, analyst consensus remains unanimously bullish with 100% buy ratings. Recent news highlights regulatory progress with partners and expansion of the drug delivery ecosystem.
The stock presents a high-risk opportunity with strong analyst support despite current losses. Investment thesis hinges on successful commercialization of neuro drug delivery technologies and partnership execution. Key risks include persistent negative cash flow from operations and delayed revenue ramp-up from new facilities. Upside depends on translating regulatory momentum into sustainable revenue growth.
Freshworks (FRSH) trades at $11.67, down 2.59% on the day, with a bullish technical signal from moving averages but a neutral RSI. The company reported strong Q2 2026 results, beating earnings estimates with $0.17 EPS, and achieved its first quarter of GAAP profitability in 2026. Revenue growth remains robust at 16% year-over-year, supported by strength in its employee experience (EX) segment, which now represents 60% of ARR.
The outlook is positive, with a consensus price target of $16.50 implying significant upside. Key opportunities include AI monetization and public sector expansion via FedRAMP progress. Risks include high valuation multiples like a 40.22 EV/EBITDA and competitive pressure in the SaaS sector. Analyst sentiment is evenly split between Buy and Hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
